51st Interscience Conference on Antimicrobial Agents and Chemotherapy

Wednesday, 22 Feb 2012

Workshop Descriptions


Workshops 51-01 - 51-08

Pharmacokinetics and Pharmacodynamics (PK/PD) have now become essential tools for determining the appropriate use of currently available anti-infective agents as well as for accelerating the development of new drugs. While this is now more and more recognized by Academia, Industry and Regulatory, there is presently a lack of training in these disciplines. The aim is to train people professionally involved in development or in the use of antiinfective drugs in the basic and applied aspects of pharmacokinetics and pharmacodynamics, showing how these sciences have emerged over the last 20 years and how their influence has grown.


51-01
Basics of Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents

8:30 a.m. - 12:00 p.m.

Upon completion of this workshop, the participant should be able to:

  • Gain insight in pharmacokinetic and pharmacodynamic concepts of antimicrobial efficacy;
  • Apply in vitro models and animal models in pharmacodynamic research;
  • Recognize the limitations and use of serum and tissue concentrations;
  • Calculate pharmacokinetic and pharmacodynamic parameters and interpret the results; and
  • Assess drug resistance in vitro.

Course Level: Beginning

Target Audience: Medical microbiologists, infectious diseases specialists, pharmacologists, drug development scientists, and other interested.

Conveners:
Hartmut Derendorf, PhD; Professor; Univ. of Florida, Gainesville, FL.
Johan W. Mouton, MD, PhD; Consultant Microbiologist; Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands.

Faculty:
William A. Craig, MD; Emeritus Professor of Medicine; Univ. of Wisconsin, Madison, WI.
Hartmut Derendorf, PhD; Professor; Univ. of Florida, Gainesville, FL.
Alasdair MacGowan, MD; Professor; Bristol Ctr. for Antimicrobial Res., Bristol, United Kingdom.
Johan W. Mouton, MD, PhD; Consultant Microbiologist; Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands.
Ursula Theuretzbacher, PhD; Principal; Ctr. for Anti-Infective Agents, Vienna, Austria.


51-02
Clinical Relevance of Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents

1:00 p.m. - 4:30 p.m.

Upon completion of this workshop, the participant should be able to:

  • Gain insight in the clinical significance of PK/PD modeling of antimicrobials;
  • Extrapolate preclinical PK/PD information into clinical drug development;
  • Determine PK/PD of antibacterials and antifungals;
  • Assess drug exposure at the site of infection; and
  • Recognize and evaluate clinical drug resistance.

Course Level: Beginning

Target Audience: Infectious diseases specialists, pharmacologists, medical microbiologists, clinical drug development specialists, and others interested

Prerequesites: A basic understanding of PK/PD, e.g. WS1

Conveners:
Johan W. Mouton, MD, PhD; Consultant Microbiologist; Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands.
Ursula Theuretzbacher, PhD; Principal; Ctr. for Anti-Infective Agents, Vienna, Austria.

Faculty:
David R. Andes, MD; Associate Professor of Medicine; Univ. of Wisconsin, Madison, WI.
Sujata Bhavnani, PharmD, MS; Vice President, Translational Medicine; Inst. for Clinical Pharmacodynamics (ICPD), Latham, NY.
Johan W. Mouton, MD, PhD; Consultant Microbiologist; Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands.
Ursula Theuretzbacher, PhD; Principal; Ctr. for Anti-Infective Agents, Vienna, Austria.
Paul M. Tulkens, MD; Professor; Univ. Louvain, Bruxelles, Belgium.
Markus Zeitlinger, MD; Professor; Med. Univ. Vienna, Vienna, Austria.


51-03
Introduction to PK/PD Modeling of Anti-Infective Agents

8:30 a.m. - 12:00 p.m.

Upon completion of this workshop, the participant should be able to:

  • Apply MIC based PK/PD modeling in vitro and in animals;
  • Perform PK/PD analysis based on kill curves;
  • Employ Population PK/PD of anti-infective agents;
  • Design and evaluate Monte Carlo Simulations; and
  • Integrate preclinical and clinical PK/PD.

Course Level: Intermediate

Target Audience: Drug development specialists, pharmacologists, medical microbiologists, infectious diseases specialists, and others interested

Prerequisites: A basic understanding of PK/PD relationships

Conveners:
Alexander A. Vinks, PharmD; PhD; Director; Univ. of Cincinnati, Cincinnati, OH.
Vincent H. Tam, PharmD; Associate Professor; Univ. of Houston, Houston, TX.

Faculty:
Sujata Bhavnani, PharmD, MS; Vice President, Translational Medicine; Inst. for Clinical Pharmacodynamics (ICPD), Latham, NY.
Jared Crandon, PharmD; Associate Director; Hartford Hosp., Hartford, CT. 
Alan Forrest, PharmD; Professor; State Univ. of New York Sch. of Pharmacy, Buffalo, NY.
Alasdair MacGowan, MD; Professor; Bristol Ctr. for Antimicrobial Res., Bristol, United Kingdom.
Vincent H. Tam, PharmD; Associate Professor; Univ. of Houston, Houston, TX.
Alexander A. Vinks, PharmD; PhD; Director; Univ. of Cincinnati, Cincinnati, OH.


51-04
Advanced PK/PD Modeling of Anti-Infective Agents With Practical Examples

1:00 p.m. - 4:30 p.m.

Upon completion of this workshop, the participant should be able to:

  • Employ sophisticated kill curve modeling;
  • Design PK/PD models to predict and avoid resistance development;
  • Integrate modeling and simulation in to the overall drug development acivities; and
  • Integrate preclinical and clinical PK/PD to streamline decision making in drug development.

Course Level: Advanced

Target Audience: Pharmacometricians, PK/PD analysts, and drug development specialists

Prequisites: A basic understanding of PK/PD relationships and modeling techniques

Conveners:
Hartmut Derendorf, PhD; Professor; Univ. of Florida, Gainesville, FL.
George L. Drusano, MD; Co-Director; Ordway Res. Inst., Albany, NY.

Faculty:
Jurgen B. Bulitta, PhD; Senior Scientist; Ordway Res. Inst., Albany, NY.
Hartmut Derendorf, PhD; Professor; Univ. of Florida, Gainesville, FL.
George L. Drusano, MD; Co-Director; Ordway Res. Inst., Albany, NY.
Alan Forrest, PharmD; Professor; State Univ. of New York Sch. of Pharmacy, Buffalo, NY.


51-05
PK/PD Full-Day Workshop Combining 51-01 and 51-02

8:30 a.m. - 4:30 p.m.

Upon completion of this workshop, the participant should be able to:

  • Gain insight in pharmacokinetic and pharmacodynamic concepts of antimicrobial efficacy;
  • Apply in vitro models and animal models in pharmacodynamic research;
  • Recognize the limitations and use of serum and tissue concentrations;
  • Calculate pharmacokinetic and pharmacodynamic parameters and interpret the results;
  • Assess drug resistance in vitro;
  • Gain insight in the clinical significance of PK/PD modeling of antimicrobials;
  • Extrapolate preclinical PK/PD information into clinical drug development;
  • Determine PK/PD of antibacterials and antifungals;
  • Assess drug exposure at the site of infection; and
  • Recognize and evaluate clinical drug resistance.

Course Level: Beginning

Target Audience: Infectious diseases specialists, pharmacologists, medical microbiologists, clinical drug development specialists, and others interested

Prerequisites: A basic understanding of PK/PD

Conveners:
Hartmut Derendorf, PhD; Professor; Univ. of Florida, Gainesville, FL.
Johan W. Mouton, MD, PhD; Consultant Microbiologist; Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands.
Ursula Theuretzbacher, PhD; Principal; Ctr. for Anti-Infective Agents, Vienna, Austria.

Faculty:
David R. Andes, MD; Associate Professor of Medicine; Univ. of Wisconsin, Madison, WI.
Sujata Bhavnani, PharmD, MS; Vice President, Translational Medicine; Inst. for Clinical Pharmacodynamics (ICPD), Latham, NY.
William A. Craig, MD; Emeritus Professor of Medicine; Univ. of Wisconsin, Madison, WI.
Hartmut Derendorf, PhD; Professor; Univ. of Florida, Gainesville, FL.
Johan W. Mouton, MD, PhD; Consultant Microbiologist; Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands.
Alasdair MacGowan, MD; Professor; Bristol Ctr. for Antimicrobial Res., Bristol, United Kingdom.
Ursula Theuretzbacher, PhD; Principal; Ctr. for Anti-Infective Agents, Vienna, Austria.
Paul M. Tulkens, MD; Professor; Univ. Louvain, Bruxelles, Belgium.
Markus Zeitlinger, MD; Professor; Med. Univ. Vienna, Vienna, Austria.


51-06
PK/PD Full-Day Workshop Combining 51-03 and 51-04

8:30 a.m. - 4:30 p.m.

Upon completion of this workshop, the participant should be able to:

  • Apply MIC based PK/PD modeling in vitro and in animals;
  • Perform PK/PD analysis based on kill curves;
  • Employ Population PK/PD of anti-infective agents;
  • Design and evaluate Monte Carlo Simulations;
  • Integrate preclinical and clinical PK/PD;
  • Employ sophisticated kill curve modeling;
  • Design PK/PD models to predict and avoid resistance development;
  • Integrate modeling and simulation in to the overall drug development acivities; and
  • Integration of preclinical and clinical PK/PD to streamline decision making in drug development.

Course Level: Intermediate

Target Audience: Pharmacologists, medical microbiologists, infectious diseases specialists, pharmacometricians, PK/PD analysts, drug development specialists, and others interested

Prerequisites: A basic understanding of PK/PD relationships

Conveners:
Hartmut Derendorf, PhD; Professor; Univ. of Florida, Gainesville, FL.
George L. Drusano, MD; Co-Director; Ordway Res. Inst., Albany, NY.
Vincent H. Tam, PharmD; Associate Professor; Univ. of Houston, Houston, TX.
Alexander A. Vinks, PharmD, PhD; Director; Univ. of Cincinnati, Cincinnati, OH.

Faculty:
Sujata Bhavnani, PharmD, MS; Vice President, Translational Medicine; Inst. for Clinical Pharmacodynamics (ICPD), Latham, NY.
Jurgen B. Bulitta, PhD; Senior Scientist; Ordway Res. Inst., Albany, NY.
Jared Crandon, PharmD; Associate Director; Hartford Hosp., Hartford, CT.
Hartmut Derendorf, PhD; Professor; Univ. of Florida, Gainesville, FL.
George L. Drusano, MD; Co-Director; Ordway Res. Inst., Albany, NY.
Alan Forrest, PharmD; Professor; State Univ. of New York Sch. of Pharmacy, Buffalo, NY.
Alasdair MacGowan, MD; Professor; Bristol Ctr. for Antimicrobial Res., Bristol, United Kingdom.
Vincent H. Tam, PharmD; Associate Professor; Univ. of Houston, Houston, TX.
Alexander A. Vinks, PharmD, PhD; Director; Univ. of Cincinnati, Cincinnati, OH.

 

51-07
PK/PD Full-Day Workshop Combining 51-01 and 51-04

8:30 a.m. - 4:30 p.m.

Upon completion of this workshop, the participant should be able to:

  • Gain insight in pharmacokinetic and pharmacodynamic concepts of antimicrobial efficacy;
  • Apply in vitro models and animal models in pharmacodynamic research;
  • Recognize the limitations and use of serum and tissue concentrations;
  • Calculate pharmacokinetic and pharmacodynamic parameters and interpret the results;
  • Assess drug resistance in vitro;
  • Employ sophisticated kill curve modeling;
  • Design PK/PD models to predict and avoid resistance development;
  • Integrate modeling and simulation in to the overall drug development acivities; and
  • Integration of preclinical and clinical PK/PD to streamline decision making in drug development.

Course Level: Beginning/Intermediate

Target Audience: Medical microbiologists, infectious diseases specialists, pharmacologists, drug development scientists, pharmacometricians, PK/PD analysts, and others interested

Prerequisites: A basic understanding of PK/PD relationships, i.e. participation in 51-01

Conveners:
Hartmut Derendorf, PhD; Professor; Univ. of Florida, Gainesville, FL.
George L. Drusano, MD; Co-Director; Ordway Res. Inst., Albany, NY.
Johan W. Mouton, MD, PhD; Consultant Microbiologist; Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands.

Faculty:
Jurgen B. Bulitta, PhD; Senior Scientist; Ordway Res. Inst., Albany, NY.
William A. Craig, MD; Emeritus Professor of Medicine; Univ. of Wisconsin, Madison, WI.
Hartmut Derendorf, PhD; Professor; Univ. of Florida, Gainesville, FL.
George L. Drusano, MD; Co-Director; Ordway Res. Inst., Albany, NY.
Alan Forrest, PharmD; Professor; State Univ. of New York Sch. of Pharmacy, Buffalo, NY.
Alasdair MacGowan, MD; Professor; Bristol Ctr. for Antimicrobial Res., Bristol, United Kingdom.
Johan W. Mouton, MD, PhD; Consultant Microbiologist; Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands.
Ursula Theuretzbacher, PhD; Principal; Ctr. for Anti-Infective Agents, Vienna, Austria.


51-08
PK/PD Full-Day Workshop Combining 51-03 and 51-02

8:30 a.m. - 4:30 p.m.

Upon completion of this workshop, the participant should be able to:

  • Apply MIC based PK/PD modeling in vitro and in animals;
  • Perform PK/PD analysis based on kill curves;
  • Employ Population PK/PD of anti-infective agents;
  • Design and evaluate Monte Carlo Simulations;
  • Integrate preclinical and clinical PK/PD;
  • Gain insight in the clinical significance of PK/PD modeling of antimicrobials;
  • Extrapolate preclinical PK/PD information into clinical drug development;
  • Determine PK/PD of antibacterials and antifungals;
  • Assess drug exposure at the site of infection; and
  • Recognize and evaluate clinical drug resistance.

Course Level: Beginning/Intermediate

Target Audience: Drug development specialists, pharmacologists, medical microbiologists, infectious diseases specialists, and others interested

Prerequisites: A basic understanding of PK/PD relationships

Conveners:
Johan W. Mouton, MD, PhD; Consultant Microbiologist; Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands.
Vincent H. Tam, PharmD; Associate Professor; Univ. of Houston, Houston, TX.
Ursula Theuretzbacher, PhD; Principal; Ctr. for Anti-Infective Agents, Vienna, Austria.
Alexander A. Vinks, PharmD, PhD; Director; Univ. of Cincinnati, Cincinnati, OH.

Faculty:
David R. Andes, MD; Associate Professor of Medicine; Univ. of Wisconsin, Madison, WI.
Sujata Bhavnani, PharmD, MS; Vice President, Translational Medicine; Inst. for Clinical Pharmacodynamics (ICPD), Latham, NY.
Jared Crandon, PharmD; Associate Director; Hartford Hosp., Hartford, CT.
Alan Forrest, PharmD; Professor; State Univ. of New York Sch. of Pharmacy, Buffalo, NY.
Alasdair MacGowan, MD; Professor; Bristol Ctr. for Antimicrobial Res., Bristol, United Kingdom.
Johan W. Mouton, MD, PhD; Professor; Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands.
Vincent H. Tam, PharmD; Associate Professor; Univ. of Houston, Houston, TX.
Ursula Theuretzbacher, PhD; Principal; Ctr. for Anti-Infective Agents, Vienna, Austria.
Paul M. Tulkens, MD ; Professor; Univ. Louvain, Bruxelles, Belgium.
Alexander A. Vinks, PharmD, PhD; Director; Univ. of Cincinnati, Cincinnati, OH.
Markus Zeitlinger, MD; Professor; Med. Univ. Vienna, Vienna, Austria.


51-09
Current Concepts of HIV Eradication and Reservoirs: On the Road to a Cure

8:30 a.m. - 4:30 p.m.

This workshop will address the highly relevant question of how we can potentially eradicate HIV and impact HIV reservoirs. HIV infected subjects on HAART are able to control viral replication and demonstrate significant CD4 T cell restoration. We recognize that subjects on HAART demonstrate low level viral replication that may contribute to non HIV comorbidities. The recent case of a HIV+ cancer patient who received a CCR5 delta 32 bone marrow transplant has raised the idea of a “cure” for HIV. The workshop will focus on current strategies that utilize novel therapeutic approaches (HDAC inhibitors) to eradicate HIV or provide functional control of HIV replication and how we evaluate the success of this approach with novel assays.

Upon completion of this workshop, the participant should be able to:

  • Define current clinical approaches being evaluated in reducing HIV reservoirs;
  • Recognize how novel therapeutic strategies may impact HIV reservoirs;
  • Define novel approaches for HIV eradication;
  • Define novel approaches for an HIV “functional cure”; and
  • Define what laboratory tools are available to monitor HIV reservoirs.

Course Level: Intermediate

Target Audience: Primary care and ID physicians, pharmacists, epidemiologists, microbiologists and immunologists.

Conveners:
Daniel R. Kuritzkes, MD; Professor of Medicine; Brigham and Women's Hosp., Cambridge, MA.
Alan L. Landay, PhD; Professor; Rush Univ. Med. Ctr., Chicago, IL.

Faculty:
Hiroyu Hatano, MD, MHS; Assistant Adjunct Professor; San Francisco Gen. Hosp., San Francisco, CA.
Michael Lederman, MD; Professor of Medicine; Case Western Reserve Univ., Cleveland, OH.
David M. Margolis, MD; Professor of Medicine; UNC Hlth. Care, Chapel Hill, NC.
Joseph Wong, MD; Associate Professor of Medicine in Residence; Univ. of California, San Francisco, San Francisco, CA.


51-10
Antibiotic Resistance among Bacterial Pathogens: Mechanisms, Detection, and Molecular Epidemiology

8:30 a.m. - 4:30 p.m.

This workshop will address important mechanisms of antibiotic resistance among common bacterial pathogens (VISA, hVISA, MRSA, VRE, MDRSP, ESBLs including CTX-M enzymes, amp(C), carbapenem-resistant Enterobacteriaceae mediated by KPCs, metallo-beta-lactamases, etc). The workshop will also explain the mechanisms of resistance for selected classes of antibiotics as well as the PK/PD parameters of these compounds that assist in evaluating potential clinical efficacy. The session will include a discussion on the epidemiology of antimicrobial resistance both from an evolutionary and a molecular perspective.

Upon completion of this workshop, the participant should be able to:

  • Describe important antimicrobial resistance mechanisms of problematic bacterial pathogens;
  • Recommend laboratory techniques appropriate for detection of such mechanisms of resistance;
  • Explain the PK/PD parameters used to evaluate antimicrobial agents in the light of evolving resistance; and
  • Recognize various molecular and evolutionary approaches used to track the development antibiotic resistance.

Course Level: Intermediate

Target Audience: Clinical microbiologists, infectious disease physicians, clinical pharmacists with expertise and interest in infectious diseases, infection control practitioners, and clinical microbiology laboratory supervisors.

Conveners:
Stephen G. Jenkins, PhD; Professor; Weill Cornell Med. Coll., New York, NY.
Audrey N. Schuetz, MD; Assistant Professor; Weill Cornell Med. Coll., New York, NY.

Faculty:
Stephen G. Jenkins, PhD; Professor; Weill Cornell Med. Coll., New York, NY.
David P. Nicolau, PharmD; Director; Hartford Hosp., Hartford, CT.
Audrey N. Schuetz, MD; Assistant Professor; Weill Cornell Med. Coll., New York, NY.
Seth Walk, PhD; Research Investigator; Univ. of Michigan, Ann Arbor, MI.

 

51-13
Antimicrobial Stewardship in Hospitals

8:30 a.m. - 4:30 p.m.

Developed in cooperation with the ESCMID Study Group for Antibiotic Policies (ESGAP)

This workshop will provide the theoretical foundation and the practical information and tools to develop a hospital Antimicrobial Stewardship program. The focus will be on measuring, evaluating and managing antimicrobial use, and on strategies to cost-justify the program. The workshop includes methods for data collection, analysis and interpretation of antimicrobial consumption data in the individual hospital, as well as within multicenter networks. The workshop also presents strategies from successful antimicrobial management programs, methods to audit the quality of antimicrobial prescriptions, a critical review of different intervention strategies to improve antimicrobial use in health care facilities and the role of newer information technology to help improve antimicrobial drug use.

Upon completion of this workshop, the participant should be able to:

  • Select proper measurement units to describe the volume of antimicrobial use;
  • Interpret antimicrobial use data locally and within a multicenter network (Benchmarking);
  • Choose and to apply an audit methodology for monitoring the quality of antimicrobial prescriptions;
  • Identify possible intervention strategies—and their relative advantages and disadvantages-- which could be implemented in a hospital;
  • Identify the electronic antimicrobial drug prescribing aids and the advantages and disadvantages of each;
  • Describe how an individual hospital can determine if its antimicrobial management program was economically successful and if it had an impact on bacterial resistance;
  • Describe the use of biomarkers of infection that may be useful to guide the duration of therapy; and
  • Describe the elements needed to launch a stewardship program in community hospitals.

Course Level: Intermediate

Target Audience: Infectious diseases pharmacists, infection control practitioners involved in antimicrobial management, infectious diseases physicians.

Conveners:
Richard H. Drew, PharmD; Associate Professor in Medicine; Duke Univ. Med. Ctr., Durham, NC.
Inge C. Gyssens, MD; Professor; Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands.

Faculty:
Elizabeth S. D. Ashley, PharmD; Associte Director for Clinical Pharmacy Services and Infectious Diseases, Univ. of Rochester Med. Ctr., Rochester, NY.
Richard H. Drew, PharmD; Associate Professor in Medicine; Duke Univ. Med. Ctr., Durham, NC.
Robert Gaynes, MD; Associate Professor; Emory Univ. Sch. of Med., Atlanta, GA.
Inge C. Gyssens, MD; Professor; Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands.
Stephan Harbarth, MD; Senior Registrar; Geneva Univ. Hosp., Geneva, Switzerland.
Harold C. Standiford, MD; Clinical Professor of Medicine, Univ. of Maryland, Baltimore, MD.


51-14
A Year in Review: Critical Analysis and Application of Treatment Guidelines for Infectious Diseases

8:30 a.m. - 4:30 p.m.

Developed in cooperation with the Society of Infectious Diseases Pharmacists

This workshop will review treatment guidelines published in the last year and analyze evidence behind key recommendations. Questions are encouraged in this interactive discussion about the pros and cons of pharmacotherapeutic management for each disease state. Speakers will give examples of how these standards are being applied and implemented in clinical practice across the country. Treatment guidelines to be discussed include those for methicillin-resistant Staphylococcus aureus infection, skin, soft tissue and diabetic foot infections, prosthetic joint infections, urinary tract infections, antimicrobial prophylaxis for surgery, neutropenic fever, and prevention of catheter-related infections.

Upon completion of this workshop, the participant should be able to:

  • Summarize the most important treatment guidelines from 2010-11;
  • Assess the efficacy, safety, and economics of each anti-infective therapy recommended;
  • Review the literature surrounding each anti-infective therapy and how this may influence treatment guidelines and clinical practice; and
  • Formulate evidence-based treatment strategies for patients with infections.

Course Level: Intermediate

Target Audience: Infectious diseases physicians, pharmacists, clinical microbiologists, and industry scientists.

Convener:
Scott J. Bergman, PharmD. Assistant Professor; Southern Illinois Univ. Edwardsville, Springfield, IL.

Faculty:
Elizabeth S. D. Ashley, PharmD. Associate Director for Clinical Pharmacy Services and an Infectious Diseases; Univ. of Rochester Med. Ctr., Rochester, NY.
Maureen K. Bolon, MD, MS. Assistant Professor; Northwestern Univ., Chicago, IL.
Kalpana Gupta, MD (Doctor of Medicine). Chief, Section of Infectious Diseases; Veterans Admin. Boston Healthcare System, Boston, MA.
Kerry L. LaPlante, PharmD. Associate Professor; Univ. of Rhode Island, Providence, RI.
Catherine Liu, MD. Assistant Clinical Professor; Univ. of California, San Francisco, CA.

 

For questions regarding the workshops, please contact This e-mail address is being protected from spambots. You need JavaScript enabled to view it .